Incyte Corp Reports 54‑Week Phase‑3 Data for Povorcitinib in Hidradenitis Suppurativa
Incyte Corp. presented 54‑week results from its Phase‑3 STOP‑HS program at the 2026 American Academy of Dermatology Annual Meeting. The data support continued development of povorcitinib, a Janus kinase (JAK) inhibitor, for moderate to severe hidradenitis suppurativa (HS).
Study Design
The STOP‑HS program comprised two double‑blind, placebo‑controlled studies (STOP‑HS‑1 and STOP‑HS‑2) enrolling adults with moderate to severe HS. After 12 weeks of randomized treatment, participants entered an open‑label extension lasting an additional 42 weeks, bringing the total observation period to 54 weeks.
- Population: 520 randomized subjects; 490 completed the extension.
- Intervention: Oral povorcitinib 15 mg once daily vs. matching placebo.
- Primary efficacy endpoint: Reduction in HS Clinical Response (HCR) score at week 12, sustained through week 54.
- Key secondary endpoints:
- Complete abscess and inflammatory nodule (AN) clearance.
- Patient‑reported outcomes (PROs) including pain, fatigue, and Dermatology Life Quality Index (DLQI).
Efficacy Outcomes
| Endpoint | Povorcitinib (54 wk) | Placebo (54 wk) | % Difference | P‑value |
|---|---|---|---|---|
| Mean change in HCR score | –4.3 ± 1.8 | –1.2 ± 2.1 | 3.1 | <0.001 |
| Absolute AN clearance | 32 % | 8 % | 24 % | <0.001 |
| Complete abscess clearance | 18 % | 3 % | 15 % | <0.001 |
| DLQI score reduction (≥5 points) | 46 % | 12 % | 34 % | <0.001 |
| Pain VAS decrease (≥30 %) | 38 % | 10 % | 28 % | <0.001 |
Sustained improvements were evident through week 54, with no loss of response in the majority of responders. The proportion achieving complete clearance of abscesses, nodules, and draining tunnels exceeded 15 %, a clinically meaningful benchmark for HS management.
Safety Profile
Across the 54‑week period, 62 % of povorcitinib recipients reported at least one adverse event (AE). The distribution of AEs mirrored that seen in the 12‑week core studies:
- Mild‑moderate AEs (grade 1–2): 58 % (most common: nasopharyngitis, headache).
- Serious AEs (SAEs): 3 % (none deemed drug‑related).
- Discontinuations due to AE: 2 %.
No new safety signals emerged during the extended follow‑up. Laboratory abnormalities were transient and resolved without intervention.
Regulatory Status
- United States: Incyte has submitted a New Drug Application (NDA) for povorcitinib for HS to the FDA.
- European Union: A Marketing Authorization Application (MAA) is pending with the European Medicines Agency (EMA).
The company plans to submit additional regulatory filings later in 2026 for other indications—including vitiligo and prurigo nodularis—once further Phase‑3 data become available.
Implications for Clinical Practice
- Efficacy Benchmarks: The sustained HCR score reduction and high rates of AN and abscess clearance provide compelling evidence that povorcitinib may be a first‑in‑class oral therapy for moderate to severe HS, a condition with limited oral options.
- Safety Confidence: The low incidence of serious events and no new safety signals support the drug’s tolerability profile over a year‑long treatment course.
- Patient‑Reported Outcomes: Improvements in pain, fatigue, and DLQI suggest meaningful benefits in daily functioning and quality of life, factors often underappreciated in clinical trials.
Healthcare providers should monitor patients for typical JAK‑inhibitor side effects (e.g., upper respiratory infections, mild elevations in liver enzymes) and adhere to established screening guidelines for infections and malignancies.
Market and Investor Perspective
Following the announcement, Incyte’s shares exhibited modest volatility, reflecting cautious investor sentiment amid competitive developments in the HS treatment landscape. The company’s pipeline—centered on hematology, oncology, and inflammatory‑autoimmune diseases—positions povorcitinib as a key asset within its inflammation and autoimmunity franchise.
Conclusion
The 54‑week STOP‑HS data reinforce povorcitinib’s potential as an effective, well‑tolerated oral therapy for moderate to severe hidradenitis suppurativa. Pending regulatory approvals, povorcitinib may become a pivotal treatment option, improving disease outcomes and patient quality of life while addressing an unmet therapeutic need.
